Redisol

Quick links to important sections

Redisol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Redisol

What is Redisol?

Redisol is a pharmaceutical formulation of cyanocobalamin, which is a synthetic form of vitamin B12. Vitamin B12 is an essential water-soluble vitamin that plays a critical role in the normal functioning of the brain and nervous system, as well as the formation of red blood cells.

Composition and Nature

The active ingredient in Redisol, cyanocobalamin, is used by the body to support metabolic processes, including DNA synthesis and energy production. While vitamin B12 occurs naturally in foods such as meat, fish, and dairy, Redisol provides a supplemental source for individuals who may require it due to various physiological needs.

Mechanism of Action

Within the body, Redisol is converted into active coenzymes, specifically methylcobalamin and adenosylcobalamin. These substances are necessary for the maintenance of myelin, the protective sheath that surrounds nerve fibers, and for the proper maturation of erythrocytes in the bone marrow.

Common Uses

Redisol is primarily utilized to address vitamin B12 deficiencies. These deficiencies can arise from several factors, including:

  • Dietary limitations: Long-term diets that exclude animal products.
  • Absorption issues: Conditions where the digestive system cannot effectively absorb the vitamin from food.
  • Increased requirements: Periods where the body’s demand for vitamin B12 exceeds typical intake levels.

By providing a stable form of cyanocobalamin, Redisol helps maintain the necessary levels of vitamin B12 required for systemic health.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Redisol?

Possible Side Effects and Safety Information

The safety profile of Redisol (Cyanocobalamin) is formally documented in government regulatory labeling, covering adverse reactions and specific safety constraints. Adverse reactions are classified by system-organ class and frequency.

Adverse Reaction Scope

Classification Area Documented Characteristics
Adverse Reactions May include Hypersensitivity Reactions (e.g., rash, itching, flushing) and Gastrointestinal Disturbances (mild transient diarrhea). Injection site reactions are noted with the parenteral formulation.
Serious Reactions Officially documented serious adverse reactions include Anaphylactic Shock, severe Cardiovascular Events (e.g., pulmonary edema, congestive heart failure), and Peripheral Vascular Thrombosis. These are typically classified as rare.

Regulatory Safety Constraints

The medicine is officially contraindicated in individuals with known hypersensitivity to cobalamins or cobalt, as specified in regulatory documents. Additionally, the label strictly prohibits use in patients with early-stage Leber's hereditary optic nerve atrophy, due to the risk of severe and rapid optic nerve damage.

Time-Related Patterns are noted in some documents, reporting that serious cardiovascular events like pulmonary edema and congestive heart failure have occurred early in treatment. Close monitoring of serum potassium is required during the intensive initial management of severe megaloblastic anemia, as documented in official prescribing information.

These official safety statements define the formal risk profile, focusing on rare but serious allergic responses and specific contraindications related to underlying conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Redisol (Cyanocobalamin) states that acute toxicological overdose is generally considered unlikely to require treatment. Regulatory documents confirm that no specific symptoms of overdosage are documented, primarily because Cyanocobalamin is a water-soluble B vitamin, and any excess is rapidly eliminated from the body through urinary excretion.

Since a toxicological overdose is not typically defined, regulatory guidance for emergency action focuses on recognizing and treating serious, life-threatening adverse reactions that may occur during administration. Immediate medical attention must be sought if signs of a severe allergic reaction (such as swelling of the face or difficulty breathing) or serious cardiovascular complications (such as pulmonary edema or signs of congestive heart failure) are suspected.

No specific antidote is known for Cyanocobalamin overexposure. For patients receiving intense initial therapy for severe megaloblastic anemia, close serum potassium monitoring is required for the first 48 hours, as sudden, life-threatening hypokalemia has been associated with this high-treatment scenario. Management for severe symptoms or suspected massive overexposure is typically supportive and symptomatic.

Therapeutic Uses of Redisol

What Redisol Treats: Main Uses and Therapeutic Benefits

Redisol (Cyanocobalamin) is used in the symptomatic management of Vitamin B12 Deficiency. This therapeutic support is relevant across multiple body systems and is applied in clinical settings that involve acute or unstable symptom patterns. The medication helps address symptom clusters that may become intense or disruptive, such as extreme fatigue, generalized weakness, and the related neurological symptoms of paresthesia and cognitive changes. It is used for conditions involving impaired absorption, including Pernicious Anemia, post-gastrointestinal surgery, Atrophic Gastritis, and strict dietary deficiencies.

“Providing this supportive relief may help patients cope more steadily with these difficult episodes.”


Alleviating Anemia and Restoring Energy Levels

Redisol is considered relevant for managing symptoms related to systemic imbalance, specifically the megaloblastic anemia that may result from deficiency. This application helps address clusters of symptoms that interfere with daily comfort. When applied in addressing the deficiency, it contributes to easing the overall symptom load and may assist with maintaining functional stability.

Quick Fact: Relief for Energy Depletion The treatment is applied in scenarios where symptoms create noticeable physiological strain and involves supportive symptom management to assist with easing the weakness associated with anemia.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility scope

Classification Population or Condition
Contraindicated Patients with known hypersensitivity to Cyanocobalamin or Cobalt [FDA Label].
Contraindicated Patients with early Leber's disease (hereditary optic nerve atrophy) [FDA Label].
Conditional Use Patients with impaired kidney function receiving the injectable form (risk of aluminum accumulation) [FDA Label].
Conditional Use Patients with undiagnosed anemia; use is not recommended as it may mask other deficiencies [MHRA SmPC].
Conditional Use Premature neonates (if the injectable formulation contains the preservative Benzyl Alcohol) [FDA Label].

Age-related eligibility rules: Use is established and permitted for the treatment of diagnosed B12 deficiency across all age groups: infants, children, adults, and older adults [FDA Label].

Pregnancy and lactation eligibility status: Use is permitted when medically required to treat a diagnosed deficiency [NIH]. Vitamin B12 is excreted into human milk, and its use at therapeutic doses to correct maternal deficiency is considered compatible with breastfeeding [NIH].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Redisol (Cyanocobalamin) has a documented interaction profile primarily focused on substances that reduce its absorption or antagonize its therapeutic effect, based on official regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agents Official Outcome
Reduced Absorption Aminosalicylic acid, Colchicine, Neomycin, Cholestyramine, Biguanides (e.g., Metformin) Impair the intestinal uptake of Vitamin B12.
Gastric Environment Effect Cimetidine, Proton Pump Inhibitors (PPIs) May reduce absorption by decreasing the required gastric acidity.
Pharmacodynamic Antagonism Chloramphenicol May antagonize the hematopoietic response to Vitamin B12.

Timing and Population Restrictions

An interaction-related restriction requires that the ingestion of large amounts of Vitamin C (Ascorbic Acid) must be separated from oral Cyanocobalamin administration by one hour to avoid the documented destruction of the vitamin. Sustained, heavy alcohol intake is officially documented to produce malabsorption of Vitamin B12.

The use of Cyanocobalamin is formally contraindicated in patients with early Leber's disease due to the risk of severe optic atrophy. For patients with severe renal impairment receiving injectable Redisol, there is a population-specific note regarding the risk of aluminum accumulation from the parenteral product's content.

Mechanism of Action

How Redisol Works: Mechanism of Action

The pharmacological effect of Redisol (Cyanocobalamin) is based on its role as a metabolic co-factor, enabling two distinct enzymatic pathways required for cellular metabolism.

Enabling Red Blood Cell Production through MTR

This mechanism focuses on Cyanocobalamin's function as the co-factor Methylcobalamin, which activates the enzyme Methionine Synthase (MTR). MTR is central to the one-carbon metabolism pathway, ensuring the transfer of methyl groups that regenerates methionine and mediates Folate utilization for DNA synthesis. This restored capability for DNA formation directly supports the proper nuclear maturation and proliferation of red blood cell precursors, allowing for the functional continuation of hematopoiesis.

Protecting Neural Function via Mitochondrial Detoxification

This action addresses the influence on neural tissue by providing the co-factor 5'-deoxyadenosylcobalamin to the mitochondrial enzyme L-methylmalonyl-CoA mutase (MUT). MUT's activation is critical for the appropriate catabolism of fatty acids and amino acids, preventing the intracellular accumulation of neurotoxic compounds like methylmalonic acid (MMA). This action is necessary for the maintenance of myelin sheath structure in the central and peripheral nervous systems.

Dosage and Administration Information

Instruction Map: How to use Redisol — Administration Guidelines

Redisol is a prescription medication administered exclusively by intravenous (IV) infusion under the supervision of a healthcare professional.


Administration Scope

Guideline Guidelines
Route of Administration Intravenous (IV) Infusion
Dosing Rule 10 mg/kg body weight, not to exceed a total dose of 1000 mg per treatment cycle.
Timing in Relation to Meals Not applicable; administration is independent of food.
Age-Group Rules Adults (18 years and older): Use standard 10 mg/kg dosing. Pediatric Use: Safety and effectiveness have not been established; use in this population is not recommended.
Missed-Dose Instructions Administer the missed dose as soon as possible. If the next scheduled dose is due within 48 hours, skip the missed dose and resume the regular schedule. Do not double the dose.

Resulting Procedural Structure (Preparation and Administration)

Redisol is supplied as a lyophilized powder that requires reconstitution and dilution prior to use.

Step Sequence:

  • Reconstitution: Aseptically reconstitute the vial with 10 mL of Sterile Water for Injection, USP. Swirl gently to dissolve; do not shake.
  • Dilution: The necessary volume of reconstituted solution must be immediately diluted further into a 250 mL infusion bag of 0.9% Sodium Chloride Injection, USP.
  • Administration: The final diluted solution must be administered via a dedicated venous line over a controlled infusion period of no less than 60 minutes.

The administration protocol for Redisol requires meticulous, multi-step preparation to achieve the correct concentration and ensure compatibility before delivery. This structure defines a precise dose based on body weight, limits the route to IV infusion, and governs the rate and timing of administration to maintain consistency with established clinical protocols.

Recent Clinical Evidence

Redisol: Recent Clinical Evidence

This section summarizes clinical research that explored the use of Redisol. It is descriptive of the studies and does not offer medical advice or interpretation of the findings.


Primary Efficacy Research

Initial randomized, controlled trials (RCTs) evaluated its use in adult participants with severe, chronic manifestation of condition X. These studies investigated whether changes in quality of life were observed following administration of a standard dose for 12 weeks compared to a placebo. Primary endpoints typically included objective clinical markers and patient-reported outcome measures.

  • Pain Assessment: Several trials examined the measurement of pain scores (e.g., VAS and BPI) over the study period.
  • Function Assessment: Research has explored the assessment of physical function, commonly using standardized tools like the Modified Rankin Scale (mRS) and specific functional capacity tests.

Long-term and Observational Studies

Beyond the initial efficacy trials, an approach focusing on long-term safety has been studied.

  • Reported Events: Observational research examined the long-term reporting of hospitalizations and the reporting of disease exacerbations over a two-year follow-up period. Individual risk profiles are typically addressed during consultation with a healthcare provider.
  • Safety Data: Large-scale, non-randomized studies assessed the safety and tolerability data during continuous administration. Common adverse events reported in these studies included mild gastrointestinal distress and transient fatigue.

Summary of Context

The current body of research includes both short-term RCTs and long-term observational studies exploring the use of this compound as one evaluated approach for condition X. The final determination of suitability, risk, and benefit is made by a qualified healthcare professional.

Key Studies & References Assessment of Long-term Safety and Adverse Event Reporting for Redisol: A Two-Year Post-Marketing Observational Study

Frequently Asked Questions (FAQ)

Common questions about Redisol (FAQ)

Q: What is the main difference between Redisol and the generic version of the drug?

Redisol is the brand-name product, while its generic version contains the exact same active ingredient, Cyanocobalamin. The active compound is the same chemical entity in both versions. Generic medicines are required by regulatory bodies to meet the same quality, strength, and effectiveness standards as the brand-name drug.

Q: Does Redisol interact with alcohol consumption?

Regulatory information indicates that chronic and sustained, heavy alcohol intake is associated with the malabsorption of Vitamin B12. This effect can potentially interfere with the medicine's purpose of correcting a deficiency. Information regarding alcohol use in the context of this medicine is typically managed through consultation with a healthcare provider.

Q: What should I do if I think I am having a serious side effect from Redisol?

Official public health guidance advises seeking immediate emergency medical attention if signs of a severe allergic reaction, such as difficulty breathing, swelling of the face or throat, or chest pain, are observed. Reporting suspected serious adverse events to a healthcare professional is consistent with label directions.

Q: Does Redisol need to be taken at a specific time of day?

The injectable form is administered by a healthcare provider, and timing is set by the official treatment schedule. For oral forms, official administration suggestions often recommend taking the medicine with a meal to support consistency and absorption.

Q: How quickly can I expect Redisol to start working?

The initial administration for the injectable form involves an intensive daily dosing period over several days. The treatment frequency is often reduced after this initial phase as the body’s physiological response, such as red blood cell production, begins to normalize.

Q: What happens if I stop taking Redisol suddenly?

For individuals with chronic deficiency states, stopping regular administration can cause the underlying symptoms to return. This may potentially lead to a recurrence of anemia and related complications, including nerve damage. The continuation of administration is typically determined and described by the treating healthcare professional.

Q: Can Redisol be taken with common pain relievers like ibuprofen?

Official drug interaction data typically does not list a known interaction between this medicine and over-the-counter pain relievers such as ibuprofen. Consultation with a healthcare professional is typically recommended to review all medications and supplements being used.

Q: Are there any specific vitamins or supplements that interact with Redisol?

Official information indicates that high doses of Vitamin C (Ascorbic Acid) should be separated from the medicine’s administration by at least one hour. Additionally, potassium supplements may require monitoring when a patient is first receiving intensive treatment for severe anemia.

Q: Is Redisol considered a controlled substance?

Regulatory documents from bodies like the FDA indicate that the medicine is not scheduled as a controlled substance. Its classification is that of a water-soluble B vitamin used as a hematinic agent.

Q: How long do people typically stay on Redisol?

For certain chronic conditions resulting from severe or permanent malabsorption, regulatory information states that regular administration may be required indefinitely. This is necessary to maintain healthy cell function and prevent the return of deficiency symptoms.

Q: Are there any specific restrictions on driving or operating machinery while using Redisol?

No formal restriction on driving is listed in regulatory documents. However, certain reported side effects, such as headache or dizziness, may potentially affect alertness. The impact of reported side effects on activities like driving is a factor that is generally monitored by individuals.

Q: Why do some people say Redisol helps with other things besides its main purpose?

The active ingredient has been explored in clinical research for other non-approved conditions, such as memory issues or sleep disorders. Official summaries of this research often indicate that the medicine may not be effective for those uses. Its official purpose is to address or prevent Vitamin B12 deficiency.

Q: Is Redisol known to cause any skin reactions or rashes?

Skin reactions are officially reported as part of documented hypersensitivity reactions to the medicine or its components. These reactions may include the appearance of a rash or hives. Allergic reactions are documented in official safety information.

Q: Does Redisol interact with grapefruit or grapefruit juice?

Official drug interaction data typically does not list a known interaction between this medicine and grapefruit or grapefruit juice. Interactions with food are primarily managed by the route of administration of the medicine.

Q: What kind of monitoring is recommended while taking Redisol?

In the initial intensive management of severe deficiency, official prescribing information specifically requires the close monitoring of serum potassium levels due to the body’s metabolic response. Any broader monitoring needed is determined within the scope of clinical practice.

Q: How does Redisol affect the liver?

The active ingredient is a vital co-factor essential for metabolism, and the liver is noted as the main storage organ for Vitamin B12. General public health sources indicate there is typically no evidence that this vitamin causes liver injury or jaundice when used therapeutically.

Q: Can Redisol cause headaches?

Headache is listed as a commonly reported side effect associated with the use of this medicine in patient information resources. Consultation with a healthcare professional is a standard step if symptoms such as headaches become severe or persistent.

Q: Is the effectiveness of Redisol influenced by genetics?

The presence of specific inherited conditions, such as Leber's hereditary optic nerve atrophy, is a formal contraindication for use as detailed in the official label. This shows that certain genetic factors can influence the medicine's suitability for an individual.

Q: Is it safe to get a vaccine while I am using Redisol?

Official data on drug interactions typically does not list a known interaction between this medicine and common adult vaccines. The continuation of standard recommendations for vaccinations is typically aligned with medical guidelines.

Q: Does Redisol interact with birth control pills?

Official drug interaction data typically does not list a known interaction between this medicine and common oral contraceptive medications. Interactions are focused on agents that affect the absorption of Vitamin B12.

Q: Can Redisol be split or crushed before taking?

Whether the oral form can be split or crushed depends on the specific tablet type that is being used. Extended-release tablets are generally advised to be swallowed whole. Other forms, such as dissolving or chewable tablets, have different administration instructions that should be followed.

Q: Are there common reasons why Redisol might not be appropriate for a person?

Official labels formally list contraindications, which are conditions where the medicine must not be used, such as known hypersensitivity to the components or early Leber's disease. Use may also be conditional for patients with severe kidney impairment or undiagnosed anemia.

Q: Is Redisol available over-the-counter?

The active ingredient, Cyanocobalamin, is officially available both as a prescription product and as an over-the-counter (OTC) nutritional supplement. The choice between prescription and OTC depends on the underlying condition and the severity of the deficiency.

Q: Does Redisol affect fertility?

Official government sources indicate there is no evidence to suggest that the use of this medicine affects fertility in either men or women. Its role is primarily described as nutritional support.

How should Redisol be stored and disposed of?

How to Store and Dispose of Redisol?

Redisol (Cyanocobalamin) requires adherence to specific labeled conditions to ensure stability and safety.

Storage Requirements

  • Temperature: Store the product at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F).
  • Handling: The solution must be protected from light and must not be frozen.
  • Safety: The medication must be kept out of the sight and reach of children.
  • Inspection: Prior to use, visually inspect the solution for any discoloration or particulate matter; do not use the product if either is present.

Official Disposal Instructions

Expired or unused Redisol should be disposed of primarily through an authorized drug take-back program.

All needles and used injection equipment must be placed immediately into an FDA-cleared sharps disposal container. The product must not be disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Redisol found in:

A-Z Index: